Patients who achieved the primary criterion for response i.e.: complete clearance or a reduction
|
|
- Imogene Hodge
- 5 years ago
- Views:
Transcription
1 MC 9101 F Study Page3 ABSTRACT Background: Cyclosporin A has been shown to be an effective systemic treatment in severe psoriasis but with the disadvantage of dose-dependent toxic effects particularly on the renal and cardiovascular systems. Calcipotriol, a recently discovered vitamin D analogue, is an effective topical agent in mild to moderate psoriasis. A combination of calcipotriol with cyclosporin A in severe psoriasis could offer enhanced efficacy with the possibility of reducing the dose and therefore the toxicity of cyclosporin A. Objectives: To compare the efficacy, safety and tolerability of the combination of calcipotriol ointment and oral cyclosporin A (CSA) with that of the combination of placebo ointment (vehicle of calcipohiol) and oral cyclosporin A in patients suffering from severe psoriasis. Patients and methods: This was a multicentre, prospective, randomised, double-blind, placebo-controlled, parallel group study consisting of a 2-week wash-out phase and a 6-week treatment phase. Patients were assessed every 2 weeks. Adult patients of either sex who had a diagnosis of psoriasis vulgaris cove~g :s SO% of body surface and with a P ASI score ~ 20 were recruited by 20 dermatologists in France and Belgium. Eligible patients were treated with calcipotriol {50 J,Lg/ g) or placebo ointment together with oral CSA in a dose of 2 mg/ kg/ day. The ointment was applied twice daily without occlusion and cyclosporin A was also taken in two divided daily doses. Patients who achieved the primary criterion for response i.e.: complete clearance or a reduction in P ASI equal to or greater than 90% of their baseline value at any visit were considered to have completed the study. Results: Seventy seven patients were recruited, 69 of whom were randomised, 35 to calcipotriol + CSA and 34 to placebo + CSA. The treatment groups were comparable with respect to age, sex-ratio and history of psoriasis and the mean PAS! before treatment was 24.7 in the calcipotriol + CSA group and 25.4 in the placebo + CSA group. This document has been do\\'n loaded from ww w.teo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment regimens, and it is provided for transpar ency and informational purposes only. The content does not reflect the complete results from au studies related to a product. As a docwnent of scientific nature it is not to be see:n as a recommendation or advice regarding the use of any products and you must always consult the specific prescribing information approved for the product prior to any prescription or use.
2 Page 4 MC 9101 F Study There were 32 patients eligible for efficacy analysis in the calcipotriol + CSA group and 34 in the placebo + CSA group. The number of patients who achieved "complete clearance" or a reduction in PASI of 01: 90% was 16 (50.0%) in the calcipotriol + CSA group and 4 (11.8%) in the placebo + CSA group (p <0.001; 95% confidence interval for between group difference 17.8% % ). The reduction in P ASI between baseline and end of treatment was statistically significant in both groups: 20.3 (80.4%) in the calcipotriol + CSA group and 14.6 (58.3%) in the placebo+ CSA group(p = 0.004; 95% confidence interval for between group difference 7.1% % ). In both patient and investigator overall assessments of treatment responses the results for caldpotriol + CSA were statistically significantly better than those for the placebo + CSA (84.4% v 64.7% achieving "clearance" or "marked improvement" as assessed by patients; 87.5% v 58.8% achieving "clearance" or "marked improvement" as assessed by investigators). Thirty adverse events (AE) were reported by 18 patients in the calcipotriol + CSA group and 25 AE's reported by 19 patients in the placebo+ CSA group (p > 0.50). Lesional or perilesional irritation was the most frequently encountered adverse event. It accounted for 27% of the 30 reported adverse events in the calcipotriol + CSA group and 24% of the 25 adverse events in the placebo+ CSA group. Three patients were withdrawn from the trial because of adverse events; 1 in the calcipotriol + CSA group [hypertriglyceridaemia) and 2 in the placebo + CSA group [pyelonephritis due to lithiasis (1 case) and muscular pain (1 case)). The results of the haematological and biochemical investigations did not reveal any clinically relevant unexpected outcome. Conclusions: The results obtained in this study in terms of efficacy, safety and tolerability suggest that the combination of calcipotriol and low dose cyclosporin A may be a useful treatment for severe psoriasis.
3 MC 9101 F Study Page 17 EXPANDED SUMMARY PROTOCOL SYNOPSIS Study objectives: To compare the efficacy, safety and tolerability of the combination of calcipotriol ointment and oral cyclosporin A (CSA) with that of the combination of placebo ointment (vehicle of calcipotriol) and oral cyclosporin A in patients suffering from severe psoriasis. Study design: A multicentre, prospective, randomised, double- blind, placebo- controlled parallel group study with 2 phases: 1) a wash-out phase lasting at most 2 weeks, and 2) a treatment phase with the combination calcipotriol (or placebo) ointment+ cyclosporin A lasting at most 6 weeks. There were assessment visits every 14 days for 6 weeks after starting double-blind treatment. Patient eligibility criteria: Out-patients or in-patients of either sex aged between 18 and 65 who presented with severe psoriasis (a PASI score of~ 20) and affected areas not exceeding 50% of the body surface and for whom treatment with cyclosporin A was indicated. Patients gave signed informed consent. Women likely to become pregnant had to use a suitable method of contraception. Patients who had guttate psoriasis, pustular psoriasis, palmar-plantar psoriasis or erythrodermic psoriasis and patients who received systemic or UV treatment for psoriasis during the previous 4 weeks were ineligible. Other reasons for exclusion were: topical treatment for psoriasis in the 2 weeks preceding visit 2,concomitant therapy likely to interfere with the study treatments or with the disease, pregnancy, breast feeding, vitamin D or calcium supplementation, intolerance to calcipotriol or cyclosporin A or exdpients, hypercalcaemia, abnormally high serum creatinine level, serum ASA Tor ALAT, alkaline phosphatase, total cholesterol or triglyceride level >2 times the upper limit of the normal range, recent or current infection, uncontrolled heart failure, neoplastic disease or immunodeficiency, weight <50 or~ 100 kg, systolic BP >160 mmhg or diastolic BP >95 mmhg, exposure to sun which might affect the course of the disease, participation in another trial in the preceding month.
4 Page 18 MC 9101 F Study Study drugs: Calcipotriol ointment 50 JA.g/ g and placebo ointment (vehicle of calcipotriol ointment) with identical appearance and consistency. The ointments were supplied in identical tubes of 30 g and were given to the patients at each visit in a quantity sufficient for use until the next visit. The maximum dosage was 4 tubes of 30 g of calcipobiol (or placebo) ointment per week. The ointment was uniformly applied on psoriatic lesions twice daily, in the morning and evening, with an interval of 12 hours, until there was complete clearance or a reduction in P ASI ~ 90% of baseline value or until the end of the 6-week treatment phase. No occlusion was used. The ointment was not to be applied to the face, the scalp, the genital region or skin folds. These regions could be treated with a topical corticosteroid of medium strength. Cyclosporin A 25 mg capsules, [SANDIMUN (Laboratoires SANDOZ)] were prescribed at each visit in a quantity sufficient to cover the time until the next visit. The dose of CSA prescribed was as close to 2 mg/kg/ d as possible. The capsules were taken every day, in the morning and evening, with an interval of 12 hours. The dose was kept constant throughout the 6-week treatment course, except in the case of the appearance of a side effect, which required a reduction of the dose of CSA, or the end of its administration, if necessary. An emollient [XERODERM (Laboratoires ROCHE POSAY)] in 125 g tubes was supplied at all centres for use during the wash-out phase. Sample size: The sample size calculation was based on an expected difference of 35% between the two groups in mean reduction of the P ASI (Psoriasis Area and Severity Index) between baseline and the end of the study, a standard deviation of 45% for this reduction in PASI, a type I error of 0.05 (a=5%) and a power of 80% (type II error, ~=20%) and showed that 6i patients (31 in each group) needed to be recruited to the study. Primary criterion for efficacy: The number of patients with complete clearance or with reduction in PASI equal to or greater than 90% of the baseline value.
5 MC 9101 F Study Page19 Assessments: The extent and severity of psoriasis for each patient were evaluated by the investigator at each visit using the Psoriasis Area and Severity Index (P ASI). The investigator and the patient had to give their overall evaluation of response to treatment compared to baseline after 2, 4 and 6 weeks of treatment. For the purpose of this evaluation, the patient and the investigator used a S point scale ("worse", "no change", "slight improve ment", "marked improvement", "completely cleared"). Adverse events were recorded by the investigator posing a non-leading question at visits 3, 4 and 5. Adverse events were scored for severity and estimated causal relationship to treatment with study drugs. A chest X-ray and 12-lead electrocardiogram were performed before starting treatment. Laboratory tests were performed as follows: a) serum levels of calcium (total), phosphate, creatinine, sodium, potassium, chloride, alkaline reserve, and blood urea {at all visits), b) serum levels of alkaline phosphatase, ALAT and ASAT, fasting total cholesterol and triglycerides (at visits 1, 2, 3, and 5), c) blood haemoglobin, red and white cell counts, differential wee, and platelet count at visits 1, 2 and 5. RESULTS SYNOPSIS Study population Seventy-seven patients were recruited by dermatologists in 20 centres in Belgium and France between October 27th 1991 and April 10th Eight patients were not randomised as 6 refused to continue in the study and in two others an exclusion criterion appeared during the wash-out phase. Thus, 69 patients were randomised, 35 to the caldpotriol + cydosporin A group and 34 to the placebo + cyclosporin A group.
6 Page 20 MC 9101 F Study Baseline characteristics of two treatment groups: The two treatment groups were comparable with respect to age, sex-ratio, duration of psoriasis, and extent and severity of psoriatic lesions evaluated using PASI as shown in the table below. Calcipotriol + CSA Placebo + CSA (n = 35) (n = 34) Age (years) Mean (SD) 44.2 (14.0) 43.3 (12.0) Range Sex-ratio No. of men (%) 23 (65.7) 24 (70.6) No. of women (%) 12 (34.3) 10 (29.4) Duration of psoriasis (months) Mean (SD) (123.3) (99.1) Range PASI Mean (SD) 24.7 (6.57) 25.4 (4.16) Range Previous therapy for psoriasis was similar in both groups. Forty four percent of the calcipotriol + CSA group and 53% of the placebo + CSA group had been previously treated with steroids. The corresponding figures for irradiation were 38% and 47% while 38% and 41% respectively had received retinoid treatment. Three patients were ineligible for the efficacy analysis due to a P ASI of 6.2 in one case and failure to use the trial medication in two others.
7 MC 9101 F Study Page21 EFFICACY Number of patients with complete clearance or improved by at least 90% of baseline P ASI at the end of treatment At the end of double-blind treatment, the number of patients who achieved the primary response criterion [a) complete clearance or b) reduction in P ASI ;a: 90%] was compared between the treatment groups. In 16 patients out of 32 (50.0%) in the calcipotriol + CSA group and in 4 patients out of 34 (11.8%) in the placebo + CSA group the primary response criterion was achieved (p < 0.001; 95% confidence interval for between group difference 17.8% ~ 58.7%).
8 Page 22 MC 9101 F Study Change in PASI PAS I: The change in P ASI from start of treatment with calcipotriol + CSA or placebo + CSA to the end of treatment is presented in the table below for all patients analyzed for efficacy. Reduction in PASI from baseline to end of treatment Calcipobiol + CSA (n = 32) Placebo +CSA (n = 34) P value Diff. in mean change (95% conf.int) VISIT 2 (BASELINE) PASI Mean (SD) Range Number (5.90) (4.16) END OF TREATMENTPASI Mean (SD) Range Number 4.88 (6.79) (8.98) Mean reduction (SO) Range Number Prob of change within group 1 > Number Equality between treatments 2 l (8.55) < (8.58) < Mean percentage reduction (SD) Upper CL Lower CL Prob of change within group 1 > Number Equality between treatments 2 > (27.52) < (32.84) < ) 2) -. One sample t-test Two sample t-test Overall assessment of response to treabnent by patients and investigators Patient's overall assessment of treatment response: The patient gave his/her overall assessment of the treatment response at each visit following start of randomised treatment. Patients' overall assessments at the end of treatment in both treatment groups are as follows:
9 MC 9101 F Study Page23 Patient's overall assessment of response at end of treatment Calcipotriol Placebo PI) + + CSA CSA (n = 32) (n = 34) Worse 0 4 No change Slight improvement 3 7 Marked improvement Completely cleared 13 4 Not assessed 0 0 l) Wilcoxon test, exact p-value, excluding "not assessed" At the end of the trial84.4% of patients considered themselves "completely cleared" or "marked improvement" in the calcipotriol + CSA group versus 64.7% in the placebo+ CSA group. Investigator's overall assessment of response at end of treatment I Calcipobiol Placebo PI) + + CSA CSA (n = 32) (n = 34) Worse 0 3 No change Slight improvement 2 9 Marked improvement Completely cleared 12 3 Not assessed 0 0 t) Wilcoxon test, exact p-value, excluding "not assessed" At the end of the trial, 87.5% of patients were assessed by the investigators as "completely cleared" or "marked improvement" in the calcipotri.ol + CSA group versus 58.8% in the placebo group. These figures are consistent with the patients' assessments. Two patients in the placebo + CSA group were withdrawn from the study due to worsening of their psoriasis.
10 Page 24 MC 9101 F Study SAFETY AND TOLERABILITY Adverse Events Thirty adverse events (AE's) were reported by 18 patients in the calcipotriol + cyclosporin A group and 25 adverse events were reported by 19 patients in the placebo+ cyclosporin A group. In the reported AE's there is no difference between the groups as regards the number of patients, the types of reactions reported, or whether the reactions were observed by the patient or the investigator. Lesional or perilesionaj irritation was the most frequently reported adverse event. It accounted for 27% of the 30 reported adverse events in the calcipotriol + CSA group and 24% of the 25 adverse events in the placebo+ CSA group. Three patients were withdrawn from the trial because of the occurrence of adverse events: 1 in the calcipotriol + CSA group [hypertriglyceridaemia] and 2 in the placebo + CSA group [pyelonephritis due to lithiasis (1 case) and muscular pain (1 case)]. Laboratory Results The results of the haematological and biochemical investigations did not reveal any clinically relevant unexpected outcome. Statistically significant elevations in mean creatinine, urea, potassium, cholesterol and ASA T levels were seen at some visits.
11 MC 9101 F Study Page 25 CONCLUSIONS Caldpotriol ointment (50 11g/ g) applied twice daily in combination with cyclosporin A orally (2 mg/kg/ d) over 6 weeks resulted in: complete clearance or a reduction in PASI of:~: 90% in 50.0% of caldpotriol + CSA treated patients compared to 11.8% in patients treated with placebo + CSA, a mean reduction in PASI of 80.4% in the active group as compared to 58.3% in the placebo group. The adverse event profile seen with the combination of caldpotriol + cyclosporin A is not significantly different from that expected from the known profile of these drugs used individually. No potentiation of adverse events was observed. The results obtained in this study in terms of efficacy, safety and tolerability suggest that the combination of caldpotriol and low dose cyclosporin A may be a useful treatment for severe psoriasis.
MC 590 ABSTRACT. PageS
This docwnent has OOen dov,nloaded from 'W'W'\VJ eo-pharma.c-om subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or
More information2 SYNOPSIS. Study code : MC 9308 FR.
MC9308 FR Study 19 December 2000 Page 15 of142 2 SYNOPSIS Study code : MC 9308 FR. Title: A comparative study of calcipotriol ointment in combination with narrow-band UVB (TL-01) phototherapy and placebo
More informationObjectives The objectives of the study were to compare the efficacy and safety of three different strengths
MC 392 Study 18 May 1998 PageS ABSTRACT Objectives The objectives of the study were to compare the efficacy and safety of three different strengths of caldpotriol cream (10, 25, 50 f!g/ g) and placebo
More information11 August 2000 Page 17 of 181. Subtitle A prospective, multicentre, randomised, double-blind, vehicle-controlled, parallel groupr comparative study.
Study MCO 9604 DE 11 August 2000 Page 17 of 181 2 SYNOPSIS Study Code MCO 9604 DE. Title Addition of Daivonex (calcipotriol) ointment (50 J.Lg!g) to fumaric acid therapy in patients with severe psoriasis
More informationLocation of study report in Regulatory Dossier for authorities
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More information: Centyr~ 1.25 mg. ~ Centyl 2.5 mg. ~ Renitec(llllO mg. Norvasc 5 mg
CE9401 DK 10 November, 1999 SYNOPSIS Studyc:ode: CE9401 OK Study title: Efficacy and safety of Centyl with potassium chloride (bendroflumethiazide) 1.25 mg and 2.5 mg compared to Renitec (enalapril) 10
More informationChemical structure of calcipotriol
PRODUCT INFORMATION DAIVONEX CREAM AUST R 57354 Calcipotriol 50 microgram/g NAME OF THE MEDICINE: CALCIPOTRIOL DESCRIPTION Calcipotriol is a white or almost white crystalline substance. It is a vitamin
More information50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).
DUPISOR Composition Gel 50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). Action Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol
More informationClinical Trial Report Synopsis
This document has been do\vnloaded from \v ww.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationPage: Pre-test screening for eligible subjects was performed during the 28 days before the anticipated study start (Day 1).
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationNail Psoriasis Blinded STUDY SYNOPSIS
Nail Psoriasis Blinded STUDY SYNOPSIS Study Title Development Phase Phase 3 Study Medication Primary Objective Secondary Objectives A randomized, double-blind, vehicle-controlled, parallel-group trial
More informationKEY MESSAGES. Psoriasis patients are more prone to cardiovascular diseases, stroke, lymphoma and non-melanoma skin cancers, and increased mortality.
KEY MESSAGES Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that affects primarily the skin and joints. Psoriasis Vulgaris is characterised by well-demarcated
More informationTopical Calcipotriol Algorithm
Topical Calcipotriol Algorithm Is this patient an adult previously diagnosed with psoriasis by a doctor? Do the skin patches look the same as those diagnosed as psoriasis? Is this psoriasis covering an
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Trial Report Synopsis. Patient insights following use of LEO aerosol foam and Daivobet gel in subjects with psoriasis vulgaris
This document has been downloaded from W\vw.leo-pharma.com subject to the ten:n.s of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationClinical Study Report Synopsis. Effect of LEO on the HPA axis and Calcium Metabolism in Subjects with Extensive Psoriasis Vulgaris
This document has been downloaded from \v v.. w.leo-pharma.com subject to the terms of use state on the webs1te. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationLocation of study report in Regulatory Dossier for authorities. Vohune: Page:
This document has been downloaded from W"\vw.leo-pharma.com subject to the tennsofuse state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationhydrochlorothiazide in the treatment of moderate arterial
Br. J. clin. Pharmac. (1987), 23, 65S-69S Determination of the optimal dosage regimen of captopril + hydrochlorothiazide in the treatment of moderate arterial hypertension D. STERU1, M. CHILDS', S. LANCRENON',
More informationIndividual Study Table Referring to Part of the Dossier. Use only) Name of Finished Product:
SYNOPSIS Fresenius Title of the study: A double-blind, randomized study comparing the safety and torelance of SMOFlipid 20% and Intralipid 20% in long-term treatment with parenteral nutrition Coordinating
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged
More informationStudy design: The study was a multicentre, prospective, randomised, doubleblind, parallel-group study.
2 11 September 1.997 Page 9 of161 SYNOPSIS FUT 9403 INT : FUCIDIN VERSUS ERYTHROMYCIN IN SKIN AND SOFT TISSUE INFECTION. A comparison of sodium fusidate tablets 250mg bd (Fucidin tablets) and erythromycin
More informationClinical Trial Report Synopsis
Clinical Trial Report Synopsis A phase 2a, proof of concept trial, testing twice daily application of LEO 124249 ointment 30 mg/g in the treatment of mild to moderate inverse psoriasis Design of trial:
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationLocation of study report in Regulatory Dossier for authorities
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 January 2012 EPIDUO, gel Tube of 30 g (CIP code: 383 814-6) Tube of 60 g (CIP code: 383 816-9) Applicant: GALDERMA
More informationLocation of study report In Regulatory (For National Authority use only) Dossier for authorities
MCB 0204FR 3 June 2003 Page 7 of86 3 SUMMARY Name of Sponsor/Manufacturer: Name Of Anished Product, If Volume: DAIVOBET /DOVOBET Title of Study/Protocol Code Number: Location of study report In Regulatory
More informationA study of treatment modalities in psoriasis in dermatology outpatient department of a tertiary care teaching hospital
Original article A study of treatment modalities in psoriasis in dermatology outpatient department of a tertiary care teaching hospital 1Y Roja Ramani, 2 Benu Panigrahy, 3 Sailenkumar Mishra, 4 BTPS Singh
More informationIs Apremilast (Otezla) Effective in Reducing Pruritus in Adults over 18 Years Old with Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 3-2017 Is Apremilast (Otezla) Effective in
More informationElements of Successful PBS Applications. Barbara Radulski RN. Copyright
Elements of Successful PBS Applications Barbara Radulski RN PBS Requirements April 1 2006 THE RULES PBS Requirements 18 years and over Psoriasis x 6 months Failed to achieve an adequate response to 3 systemic
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Net Study Comparison of clinical efficacy of topical tazarotene.1% cream with topical clobetasol propionate.5% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Psoriasis: the management of psoriasis 1.1 Short title Psoriasis 2 The remit The Department of Health has asked NICE: 'to produce
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology is intended for the treatment of: Steroid responsive dermatoses such as psoriasis and seborrheic dermatitis of the hairy regions,
More informationClodronate BE/H/PSUR/001/001 October 2011 Agreed CSP
Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationSYNOPSIS. Abbreviated Clinical Study Report. Study Code: RIMON_L_01031 Document Status: Synopsis V 2.1 Date: 16-Oct Title of the study:
SYNOPSIS Title of the study: Investigator(s): A 12-month multicentre, randomised, double-blind, placebo-controlled study with two parallel groups to assess the effects of rimonabant 20 mg in patients with
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More information13 August Fucidin-H vs. Hydrocortisone in Atopic Dermatitis.
FUH9401DK 13 August 2002 Page 11 of108 2 SYNOPSIS Study code number FUH9401 DKStudy Study title Fucidin-H vs. Hydrocortisone in Atopic Dermatitis. Study Subtitle A comparative study of Fucidin-H cream
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationA systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C
A systematic review of treatments for severe psoriasis Griffiths C E, Clark C M, Chalmers R J, Li Wan Po A, Williams H C Authors' objectives To compare the effectiveness of currently available treatments
More informationA Pilot Study. Name of investigational product:
An Open Label, Multi Center Clinical Study to Evaluate the Efficacy and Safety of a New Topical Cosmeceutical in Relieving the Redness, Scaling and Flaking Associated with Severe Skin Conditions A Pilot
More informationSynopsis. Study Phase and Title: Study Objectives: Overall Study Design
Synopsis Study Phase and Title: Study Objectives: Overall Study Design Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
2 Synopsis Title of study: An Investigator-blind, Controlled Study to Assess the Efficacy and Safety of Different Formulations of Compared to Placebo and to Active Control in a Psoriasis Plaque Test Investigators
More informationPrimary Response Criterion; Mean change (from baseline (visit 2) to end of treatment) in total sign score'l 1
MC 492 Study PageS ABSTRACT Objectives The objectives of the study were to compare the efficacy and safety of three different strengths of caldpotriol gel (10, 25, 50 f,lg/ g) and placebo gel (vehicle)
More informationPATIENT INFORMATION LEAFLET. Urea 10% w/w Cream
PATIENT INFORMATION LEAFLET Urea 10% w/w Cream Read all of this leaflet carefully because it contains important information for you. This medicine is available without prescription. However, you still
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationVemurafenib (Zelboraf ) BRAF V600 mutation positive Metastatic Melanoma
Vemurafenib (Zelboraf ) BRAF V600 mutation positive Metastatic Melanoma Background: Vemurafenib has been approved by NICE for the treatment of BRAF V600 mutation positive unresectable or metastatic melanoma.
More informationAppendix 1: Frequently Asked Questions
Appendix 1: Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added to the Ontario Drug Benefit (ODB) Formulary
More informationDEMOGRAPHICS PHYSICAL ATTRIBUTES VITAL SIGNS. Protocol: ABC-123 SCREENING. Subject ID. Subject Initials. Visit Date: / / [ YYYY/MM/DD]
SCREENING Visit Date: DEMOGRAPHICS / / [YYYY/MM/DD] Consent Signed Date and time / / [YYYY/MM/DD] : Has written assent been obtained? If no, why not? YES NO Gender: Male Female Birthdate: Permission given
More informationUsing Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice)
Using Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice) Patient Case Study in Psoriasis Patient Case Study in Psoriasis William Smith,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Calcipotriol/Betamethason Sandoz 50 microgram/g + 0,5 mg/g, zalf
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Calcipotriol/Betamethason Sandoz 50 microgram/g + 0,5 mg/g, zalf 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains
More informationPackage leaflet: Information for the user. Fluticrem 0.05% cream Fluticasone propionate
Package leaflet: Information for the user Fluticrem 0.05% cream Fluticasone propionate Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationOntario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions
Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS. NAME OF THE MEDICINAL PRODUCT Daivobet 50 micrograms/g + 0.5 mg/g gel 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of gel contains 50 micrograms of calcipotriol
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationStudy No: Title: Rationale: . Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationPage 16 of January 2000 MCO 9503 INT Study
Page 6 of6 5 January MCO 953 INT Study weeks. Throughout all phases of the study the interval between control visits was3weeks. Number of patients A total of patients was to be recruited to obtain 4 evaluable
More informationStudy Population: 12 years and older A EF Calcipotriene Foam, 0.005%
Study No.: CAL.203 Title: A Randomized, Open-Label Study to Assess the Bioavailability of Emulsion Formulation Foam, 0.005%, and Dovonex, 0.005%, in Patients with Mild to Moderate Plaque-Type Psoriasis
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More information3. Has the patient shown improvement in signs and symptoms of the disease? Y N
Pharmacy Prior Authorization MERC CARE (MEDICAID) Renflexis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationGemcitabine & Cisplatin
Gemcitabine & Cisplatin Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Advanced
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationEvaluation of Imuspora Tablets and Ointment (Multi-Ingredient Herbal Formulation) In the Management of Psoriasis: An Open Trial
Evaluation of Imuspora Tablets and Ointment (Multi-Ingredient Herbal Formulation) In the Management of Psoriasis: An Open Trial Background: D G Saple*, S Medhekar** & M Patil*** *Professor & Head, Department
More informationFullerton Healthcare Screening Centres
Fullerton Healthcare Screening Centres Fullerton Healthcare Screening Centre @ Ngee Ann City The Penthouse, #26-02 Ngee Ann City Tower B, 391B Orchard Road, Singapore 238874 Operating hours: Monday - Friday
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris Peeters P, Ortonne
More informationHorizon Scanning Centre March Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209
Horizon Scanning Centre March 2015 Ixekizumab for moderate to severe chronic plaque psoriasis SUMMARY NIHR HSC ID: 5209 This briefing is based on information available at the time of research and a limited
More informationClinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationLung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA310 First line treatment option in locally advanced or metastatic NSCLC Positive test for epidermal growth factor receptor
More informationProtocol Number: BV-2005/01. OM Pharma OM-85
Page 3 SYNOPSIS Protocol Number: Name of Finished Product: Broncho-Vaxom (Broncho-Munal ) Title: Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom in Children Suffering from
More informationBetamethasone dipropionate
NEW ZEALAND DATA SHEET Daivobet 50/500 ointment Calcipotriol 50 microgram/g Betamethasone 500 microgram/g present as dipropionate NAME OF THE MEDICINE Daivobet 50/500 ointment OH H H H 2 O HO OH Calcipotriol
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAcute Stroke with Alteplase Administration Order Set
Review Due Date: 2017 October PATIENT CARE DERS Weight: Adverse Reactions or Intolerances Drug No Yes (list) Food No Yes (list) _ Latex No Yes Admission Admit to Neurology service: Dr. Critical Care Diagnosis:
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Perfan Injection 100 mg/20 ml Concentrate for Solution for Injection Active substance: enoximone Read all of this leaflet carefully before you
More informationSYNOPSIS (PROTOCOL WX17796)
TITLE OF THE STUDY A prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter, 52-week trial to assess the efficacy and safety of adjunct MMF to achieve remission with reduced
More informationPFIZER INC. GENERIC DRUG NAME and/or COMPOUND NUMBER: 5% Spironolactone Cream/ PF
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThe Ointment is back!
Now Available for Plaque Psoriasis The Ointment is back! Bioequivalent to Dovonex * Ointment Before prescribing, please see attached full Prescribing Information. The same Delivers the reliability you
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. SODIPHOS 22mEq / 10ml Concentrate for solution for infusion. Disodium phosphate dihydrate
PACKAGE LEAFLET: INFORMATION FOR THE USER SODIPHOS 22mEq / 10ml Concentrate for solution for infusion Disodium phosphate dihydrate Read all of this leaflet carefully before you start using this medicine.
More informationSubject ID: I N D # # U A * Consent Date: Day Month Year
IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be
More informationThe chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:
Acyclovir Ointment, USP 5% DESCRIPTION Acyclovir, USP, is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment, USP 5% is a formulation for topical administration. Each gram
More informationPFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationNatpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary
Natpara (parathyroid hormone) Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Agent Indication Dosing and Administration Natpara (parathyroid hormone) subcutaneous
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 MOZOBIL 20 mg/ml, solution for injection Box containing 1 vial (CIP: 397 153-7) Applicant: GENZYME
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More information